In Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cell lines exhibiting the latency I form of infection (i.e., EBV nuclear antigen 1 [EBNA1J positive in the absence of other latent proteins), the EBNA1 mRNA has a unique BamHI Q/U/K splice structure and is expressed from a novel promoter, Fp, located near the BamHI FQ boundary. This contrasts with the situation in EBV-transformed lymphoblastoid cell lines (LCLs) exhibiting the latency III form of infection (i.e., positive for all latent proteins), in which transcription from the upstream Cp or Wp promoters is the principal source of EBNA mRNAs. We carried out cDNA amplifications with oligonucleotide primer-probe combinations to determine whether Fp is ever active in an LCL environ- small subpopulation of cells which have switched spontaneously from latency III into lytic cycle. The mechanism of switching is not understood, but the first detectable change in viral gene expression is an activation of the EBV immediate-early genes BZLF1 and BRLF1 (14); the protein products of these genes then initiate the lytic-cycle cascade (2, 9, 18, 38) .
Epstein-Barr virus (EBV), a herpesvirus widespread in human populations, is able to infect at least two lineages of target cell in vivo, stratified pharyngeal epithelium and B lymphocytes. While the infection in epithelium appears to be largely productive (lytic) (16) , B cells can harbor the virus as a nonproductive (latent) infection, thereby providing both a means of virus persistence and a reservoir from which infectious virus can be obtained by reactivation (33, 55) . It is now apparent that EBV can adopt more than one form of latency in lymphocytes and that these alternative forms of infection are associated with distinct programs of viral transcription and viral promoter usage.
The standard in vitro model for EBV latency is that seen in virus-transformed lymphoblastoid cell lines (LCLs) produced by experimental infection of normal resting B cells (reviewed in references 26 and 50). In such lines, there are two major families of mRNA transcripts. Transcription from the BamHI C promoter (Cp) or from the adjacent BamHI W promoter (Wp) gives rise to mRNAs for each of the six EBV nuclear antigens (EBNAs), 1, 2, 3A, 3B, 3C, and LP (53) , while transcription from promoters in BamHI N gives rise to mRNAs for each of the latent membrane proteins (LMPs), 1, 2A, and 2B (22, 28, 44) . This pattern of virus gene expression we now refer to as latency III. Note that LCLs either are completely nonproductive of virus particles or else contain a small subpopulation of cells which have switched spontaneously from latency III into lytic cycle. The mechanism of switching is not understood, but the first detectable change in viral gene expression is an activation of the EBV immediate-early genes BZLF1 and BRLF1 (14) ; the protein products of these genes then initiate the lytic-cycle cascade (2, 9, 18, 38) .
Studies of the EBV-associated B-cell malignancy Burkitt's lymphoma (BL) have identified an alternative form of latency (latency I) characterized by selective expression of just one of the latent proteins, EBNA1 (17, 41) . In this situation, the Cp/Wp and LMP promoters used in LCL cells are not active; instead, a unique BamHI Q/U/K-spliced EBNA1 mRNA is expressed from an alternative promoter, Fp, near the BamHI F/Q boundary (42, 45 (17) .
The transcriptional differences between these alternative forms of EBV latency are at present understood only in outline, and many of the controls governing virus promoter usage remain to be elucidated. An immediate issue which we wished to resolve stemmed from recent work using cDNA Analysis of EBV protein expression. Western blot analysis of endogenous and recombinant vaccinia virus-encoded EBV protein expression was performed as described elsewhere (17) . Briefly, cell pellets were lysed in SDS-gel sample buffer, sonicated, boiled for 2 min, electrophoresed on a discontinuous SDS-acrylamide gel, and transferred to nitrocellulose filters. Samples were routinely separated on discontinuous Laemmli gels with 7.5% acrylamide resolving gels except that samples destined to be probed for the 17-kDa BHRF1 protein were resolved on a 10% acrylamide gel. The nitrocellulose filters were blocked with skim milk before being probed overnight with either polyspecific human sera or murine monoclonal antibodies. Reactive antibodies from the human sera were detected by incubating the filters with "2I-protein A, while specific binding of monoclonal antibodies was detected with 125I-protein A after the filters were first incubated with rabbit antibodies to mouse immunoglobulin G. For the detection of EBNAs 1, 2, 3A, 3B, and 3C, three selected human sera (PB, RS22, and AMo) were pooled and used diluted 1:100. For the simultaneous detection of several EBV lytic-cycle proteins, serum EE was used diluted 1:400. Under these conditions, serum EE shows weak reactivity with only one of the EBV latent proteins, EBNA2, but has unusually strong reactivity against several lytic-cycle proteins, including the immediate-early proteins BZLF1 and BRLF1 and the two major components of the early antigen EA(D) complex, BSLF2-BMLF1 and BMRF1. Note that serum EE does not detect the BHRF1 protein, a component of the early-antigen EA(R) complex; expression of BHRF1 was therefore determined by using the monoclonal antibody 5B11 (34) .
Analysis of EBV lytic-cycle protein expression was also performed by indirect immunofluorescence staining of acetone-fixed cell smears with monoclonal antibodies as described elsewhere (40) . The monoclonal antibodies used were BZ.1, which is reactive with BZLF1 (57); R3, which is reactive with BMRF1 (35); 5B11, which is reactive with BHRF1 (34); R63, which is reactive with BORF2, another component of the EA(R) complex (15); 72A1, which is reactive with the late membrane antigen gp340 (20) ; and V3, which is reactive with the late viral capsid antigen (VCA) (52 (27, 39) . We therefore screened the entire panel of LCLs used as described above for virus producer status and found a complete concordance between the presence of a subpopulation of lytically infected cells and the detectability of an Fp-driven EBNA1 transcript. Figure 2A illustrates the pattern of results obtained when protein extracts of the 10 LCLs screened in Fig. 1 were analyzed for latent-cycle antigens (EBNAs 1, 2, 3A, B, and C; Fig. 1 order to provide an independent index of virus producer status based on mRNA rather than protein analysis, we developed a PCR-based assay specific for the spliced 1.7-kb BHRF1 mRNA, an abundant transcript of the early lytic cycle (see class IV BHRF1 cDNA structure discussed in reference 34). As shown in Fig. 2B , this transcript was again restricted to the subset of LCLs which had been identified by immunoblotting as productive (cf. Fig. 2A ) and which contained Fp-initiated transcripts (cf. Fig. 1 ).
Fp usage in ACV-treated producer cell lines. We next selected a number of LCLs for treatment with the nucleoside analog acyclovir (ACV), which is a proven inhibitor of EBV DNA replication that blocks progression from the early to the late phase of the lytic cycle (30) . Figure 3 shows the results of PCR analysis of EBNA1 transcripts in three spontaneously productive cell lines (B95.8, JT/B95, and DH/B95) after maintenance for 14 days either in normal medium or in the presence of an inhibitory concentration (200 ,M) of ACV. In each case, prolonged ACV treatment did not reduce the detectability of Q/U/K-spliced transcripts.
At the same time, immunofluorescence staining of these ACV-treated LCLs for early-and late-lytic-cycle antigens confirmed the blockade of late lytic cycle.
Further experiments sought direct evidence that PCR detection of Q/U/K-spliced mRNAs in such lines was indeed associated with the presence of Fp-initiated transcripts. Two cell lines (B95.8 and AG876) with relatively high proportions of cells in lytic cycle (6 to 18%) and with easily detectable Q/U/K-spliced transcripts were cultured for 14 tection of a 40-nucleotide (nt) fragment of the Cl probe by RNA from the Cp-using B95.8 cell line (53) , there was also clear protection of 50-and 44-to 47-nt fragments of the FQ probe; this exactly mirrors the pattern of FQ protection already seen with EBNA1 mRNA from group I BL cells (42) . The Wp-using AG876 cell line likewise showed protection of 50-and 44-to 47-nt fragments of the FQ probe, in this case along with the expected protection of a 40-nt fragment of the WOW1 probe (54) . Again, ACV treatment had no effect on the detectability of Fp-initiated transcripts (Fig. 4) .
BZLFl-mediated lytic-cycle entry activates Fp usage. The final set of experiments sought independent evidence for a link between lytic-cycle entry and Fp usage. It is known that the EBV immediate-early gene product BZLF1 is capable of activating the lytic cycle (9, 38), and we therefore first used the recombinant vaccinia virus Vacc-BZ to express BZLF1 in two nonproductive LCLs: X50-7, which is known to express EBNA transcripts from Wp (53), and SG/B95, which (in common with most established LCLs) expresses EBNA transcripts from Cp.
To confirm vaccinia virus-mediated expression of BZLF1, protein extracts from these two cell lines and from EBVnegative cell line 143 were prepared 12 h following infection with Vacc-BZ or with Vacc-TK-as a control. Figure 5A shows the results obtained when such extracts were immunoblotted and probed with the polyvalent human serum EE. It is clear that vaccinia virus-expressed BZLF1 is detectable in both LCLs as well as in 143 cells as a series of bands, i.e., a major band with an apparent molecular weight of 39, 000 and two minor bands at higher apparent molecular weights (presumed to be multimers). Within the time frame of this experiment, we could find no evidence that Vacc-BZ infection of SG/B95 cells had induced any other antigens of the EBV lytic cycle, whether assayed by immunoblotting (Fig.  5A) or by monoclonal antibody staining for individual proteins of the early-antigen complex, namely, BMRF1, BHRF1, and BORF2 (data not shown). In the Vacc-BZinfected X50-7 cells, however, we did observe induced expression of another protein of the early-antigen complex, naniely, BSLF2-BMLF1, visualized as a major 60-kDa band J. VIROL. and smaller minor species (8) in immunoblots (Fig. 5A) . Monoclonal antibody staining of the same cells for other early-antigen components remained negative (data not shown).
EBNA1 BamHI F PROMOTER AND LYTIC CYCLE
Analysis of RNA preparations made at the same time from the panel of control and recombinant vaccinia virus-infected LCL cells described above clearly showed that a Q/U/Kspliced EBNA1 transcript was induced as a result of Vacc-BZ infection. Figure 5B shows the results of one of several successive experiments of this kind; in each experiment, the Q/U/K-spliced PCR product was detectable after 12 h in Vacc-BZ-infected cells. When analyzed at regular intervals postinfection, the Q/U/K-spliced transcripts first appeared between 6 and 12 h postinfection in contrast to BZLF1 protein, which was first detectable at 2 h postinfection.
In further studies using X50-7 target cells, we asked whether vaccinia virus-mediated expression of other immediate-early or early proteins of the EBV lytic cycle could mimic the effect of BZLF1. The recombinants tested alongside Vacc-BZ included Vacc-BR, which encodes the 98-kDa immediate-early protein BRLF1; Vacc-BM, which encodes slightly truncated forms (designated BMLF1) of the 60-kDa early-antigen component BSLF2-BMLF1; and Vacc-BH, which encodes the 17-kDa early-antigen component BHRF1. Figure 6A shows immunoblots of protein extracts made from cells 12 h after infection with each of these individual recombinants or with Vacc-TK as a control. In the upper panel, these blots were probed with the polyvalent human serum EE (reactive against all the lytic-cycle antigens named above except BHRF1), and in the lower panel, they were probed with the BHRFl-specific monoclonal antibody 5B11.
It is clear that each vaccinia virus recombinant expresses the relevant EBV lytic-cycle protein in X50-7 cells at levels in excess of those seen in extracts of the spontaneously productive B95.8 cell line. However, when RNA preparations made in parallel from these same vaccinia virus-infected cells were screened by PCR analysis, activation of Q/U/Kspliced EBNA1 transcripts was observed only with the Vacc-BZ recombinant (Fig. 6B ).
DISCUSSION
Studies of a variety of cell culture and tumor systems have helped identify three forms of EBV latency. In latency 1, exemplified by BL cell lines retaining the group I cell phenotype, EBNA1 is expressed in the absence of all other latent proteins (17, 41) . In latency II, exemplified by the EBV-positive epithelial tumor nasopharyngeal carcinoma, EBNA1 is expressed along with the-LMPs (3, 5, 10, 48, 56 Fig. 1 and 2) . from the prototype virus-producing AG876, each with a relatively large i lytic cycle, were used, S1 nuclea, showed that transcripts were being i] same sites within Fp (Fig. 4) (Fig. 3 and 4 (40) . Interestingly, in Si nuclease protection assays of the kind illustrated in Fig. 4 , we found it much easier to detect Fp-initiated transcripts in the spontaneously productive B95.8 and AG876 cell lines than in group I BL cells (28a), indicating a marked difference in the abundance of these transcripts in the latent versus lytic situations. Recent work on Fp activity in latent infection suggests an important negative autoregulatory role for the EBNAl protein itself that is mediated via EBNA1 binding to consensus sequences in BamHI Q downstream of the transcription start site (43) . One possibility is that this usually strong autoregulatory loop is relaxed in lytic cycle, allowing increased Fp transcription. The importance to the virus of this activation of Fp in lytic cycle remains to be determined; there may yet be a role for EBNA1 or for some other protein encoded by an Fp-initiated transcript in the virus replicative cycle.
